

RESEARCH

Open Access



High urinary excretion of kidney injury molecule-1 predicts adverse outcomes in acute kidney injury: a case control study

Yuanyuan Xie^{1,2†}, Qin Wang^{1,2†}, Chunlin Wang^{1,2}, Chaojun Qi^{1,2}, Zhaohui Ni^{1,2} and Shan Mou^{1,2*}

Abstract

Background: Acute kidney injury (AKI) is a common clinical syndrome with poor prognosis. The insensitivity and non-specificity of traditional markers of renal dysfunction prevent timely estimation of the severity of renal injury, and the administration of possible therapeutic agents. Urinary kidney injury molecule-1 (uKIM-1) is a marker of epithelial injury of renal tubules. Different uKIM-1 levels are associated with various degrees of renal injury. This study sought to evaluate uKIM-1 as a predictor of renal prognosis by analyzing uKIM-1 levels in patients with AKI.

Methods: A total of 258 patients were screened, 201 patients were enrolled in the study, and 17 patients were lost to follow up. Therefore, 184 AKI patients were included in this study and were classified into transient AKI and renal AKI groups according to short-term renal function recovery (48 h). Changes in renal function were observed for one year during regular follow up, and risk factors that affected renal prognosis were analyzed.

Results: The uKIM-1 level in the renal AKI group was significantly higher than that in the transient AKI group. The receiver operating characteristic area under the curve (ROC-AUC) of uKIM-1 for the diagnosis of renal AKI was 0.691, and its sensitivity and specificity were 66.3 % and 64.7 %, respectively. The uKIM-1 level at AKI occurrence was significantly higher in the group with deterioration in renal function than in the group with stable renal function. Thus, uKIM-1 level is a prognostic factor for poor renal prognosis. ROC curve analysis demonstrated that the AUC for the prediction of renal function progression on the basis of uKIM-1 levels in patients with renal AKI and AKI was 0.680 and 0.703, respectively; the sensitivity was 78.6 % and 78.4 %, respectively; and the specificity was 57.9 % and 60.8 %, respectively. uKIM-1 > 2.37 ng/mg in patients with AKI positively correlated with poor renal prognosis.

Conclusions: uKIM-1 levels sensitively predict the renal prognosis of patients with AKI, and they may be used as early screening indicators for poor renal prognosis.

Keywords: Acute kidney injury, Urine kidney injury molecule-1, Renal AKI, Transient AKI, Long-term outcomes

Abbreviations: AKI, Acute kidney injury; CKD, Chronic kidney disease; eGFR, Estimated glomerular filtration rate; ESRD, End-stage renal disease; FeNa, Fractional excretion of sodium; RFI, Renal failure index; ROC-AUC, Receiver operating characteristic area under the curve; sCr, Serum creatinine; uCr, Urine creatinine; uKIM-1, Urinary kidney injury molecule-1

* Correspondence: shan_mou@shsmu.edu.cn

†Equal contributors

¹Department of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China

²Shanghai Center for Peritoneal Dialysis Research, Shanghai, People's Republic of China

Background

Acute kidney injury (AKI) is one of a number of conditions that affect kidney structure and function. AKI is defined by an abrupt decrease in kidney function. It is a broad clinical syndrome encompassing various types of etiology [1]. AKI has a high incidence rate, and it is an increasingly common complication associated with poor prognosis in hospitalized patients. AKI consumes a large amount of social and medical resources, but there is a shortage of effective therapeutic regimens [2, 3]. The kidney normally exhibits an extremely strong capacity for self-regeneration and repair, and can recover from mild and moderate injury [4]. However, incomplete renal repair can result in chronic kidney disease (CKD) in some cases [4, 5]. In recent years, the incidence rate of CKD has annually increased with the increasing incidence rate of AKI [6]. Numerous studies have found that renal function in some patients with AKI does not recover completely but gradually progresses to CKD and end-stage renal disease (ESRD), and may require permanent renal replacement therapy [2, 6, 7]. Urinary kidney injury molecule-1 (uKIM-1) is a marker of epithelial injury of renal tubules, and it is elevated in the early stages of AKI [8]. Different uKIM-1 levels are associated with various degrees of renal injury. This study examined the value of uKIM-1 level in identifying reversible renal injury and its predictive value for long-term prognosis by examining renal function recovery during short-term and long-term prognoses in patients with AKI.

Methods

Study subjects

Male and female inpatients ≥18 years of age with complete clinical data who were diagnosed with AKI or

acute-on-chronic kidney injury (A on C) were enrolled in this study. Minor patients and patients with a life expectancy less than one year because of malignant disease were excluded. AKI was defined and staged using the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Acute Kidney Injury [1].

Our study was conducted at Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, P.R. China, a 2000-bed teaching hospital. The subjects were recruited from all hospital departments (both surgical and non-surgical), including ICU.

Sampling

Fresh urine and blood samples were obtained from each patient at the time of AKI diagnosis and at 24 h and 48 h, and at the 3-month, 6-month, and 12-month follow up, and they were submitted to a biochemical laboratory for analysis. Fresh urine (10 ml) collected from each patient at the time of AKI diagnosis was centrifuged at 1000 × g for 15 minutes, and the liquid supernatant was placed into Eppendorf tubes and stored at -80 °C until subsequent analysis.

Detection of indicators

Serum creatinine (sCr) and urine creatinine (uCr) were detected using enzymatic methods. A simplified formula for the modification of diet in renal disease (MDRD) was used to calculate the estimated glomerular filtration rate (eGFR):

$$eGFR = 186 \times (sCr/88.4)^{-1.154} \times Age^{-0.203} \times (0.742, \text{Female}) [9].$$

An enzyme-linked immunosorbent assay (ELISA) was performed to detect urine kidney injury molecule-1




Fig. 1 Study flow chart. AKI acute kidney injury

(uKIM-1) using a kit from the American R&D Corporation (Minneapolis, MN, USA). The concentration of the tested sample was calculated using a standard curve, and the results are expressed in ng/mg after synchronous uCr correction. Fractional excretion of sodium (FeNa) was calculated as follows:

$$\text{FeNa} = \frac{(\text{Plasma creatinine} \times \text{Urinary Na})}{(\text{Plasma Na} \times \text{Urinary creatinine})}$$

The renal failure index (RFI) was calculated as follows:

$$\text{RFI} = \frac{(\text{Urinary Na} \times \text{Plasma creatinine})}{\text{Urinary creatinine}}$$

Grouping

Patients with AKI were divided into transient AKI and renal AKI groups according to changes in renal function within 48 h. Transient AKI was defined as a reversal within 48 h [10]. Renal AKI was defined as non-transient AKI when no recovery was observed within 48 h [10]. Recovery of AKI was determined as reduction of serum creatinine from the peak to less than 0.3 mg/dl above baseline [10]. We also corrected sCr for fluid balance [11]. No patients received blood transfusions.

Patients with AKI and patients with renal AKI patients were classified into two groups during one year of follow up: a group with stable renal function and a group with deterioration in renal function. Deterioration in renal function was defined as a one-stage reduction in GFR accompanied by a 25 % or greater reduction in eGFR from baseline [12].

Statistical analysis

SPSS13.0 statistical software IBM (NY, USA) was used. Normally distributed measurement data are expressed as mean \pm sd, and the *t* test was used for group comparisons. Measurement data with a non-normal distribution are expressed as the median (M) and interquartile range (P25, P75). The rank sum test was used for comparisons between groups. Spearman correlation analysis was used to analyze correlations. A receiver operating characteristic (ROC) curve and the area under curve were used to calculate the sensitivity and specificity. Logistic regression analysis was used to analyze related risk factors that influenced the prognosis of kidney function. Cox multifactor regression analysis was used to analyze the relationship between all risk factors and the life span of the kidneys. Survival rate was analyzed using a Kaplan-Meier life survival curve. A difference of $P < 0.05$ was considered statistically significant.

Results

General data

A total of 258 patients were screened, 201 patients were enrolled in the study, and 17 patients were lost to follow up. Therefore, 184 patients with AKI (86 patients with transient AKI and 98 patients with renal AKI) were included in the study. All the 184 patients survived to one-year follow up. After regular follow up for one year,

Table 1 General condition of patients

Characteristics	Values (n = 184 patients)
Age, years	53.00 (31.00, 64.75)
Male sex (n, %)	117 (63.59 %)
Oliguria (n, %)	9 (4.9 %)
Baseline serum creatinine (mg/dl)	1.12 (0.87, 2.40)
Baseline estimated GFR (ml/min/1.73 m ²)	66.68 (28.10, 94.18)
Baseline 24 hUTP (g/24 h)	3.78 (1.47, 9.08)
sAlb (g/l)	33.30 (24.00, 40.25)
Hb (g/l)	119.00 (99.25, 140.00)
ALT (U/l)	14.00 (10.00, 23.00)
AST (U/l)	17.00 (14.00, 25.75)
Ca (mmol/l)	2.08 (1.99, 2.22)
P (mmol/l)	1.32 (1.10, 1.56)
K (mmol/l)	3.90 (3.40, 4.30)
HCO ₃ ⁻ (mmol/l)	24.20 (20.90, 26.40)
hsCRP (mg/l)	2.40 (0.80, 8.17)
Cause of AKI (n %)	
Ischemia	40 (21.74 %)
Nephrotoxicity	37 (20.11 %)
Infection	42 (22.83 %)
Glomerular disease	35 (19.02 %)
Obstruction	21 (11.41 %)
Others	9 (4.90 %)
AKI stage, n	
Stage 1	123
Stage 2	26
Stage 3	35
Peak serum creatinine (mg/dl)	2.43 (1.41, 3.74)
uKIM-1 (ng/mg)	2.37 (1.10, 6.22)
FeNa \geq 1 % (n %)	126 (68.48 %)
RFI \geq 1 % (n %)	136 (73.91 %)
Renal AKI (n %)	98 (53.26 %)
Progression of renal failure (n %)	73 (39.67 %)

Conversion factor for serum creatinine in mg/dL to mmol/L, $\times 88.4$. AKI acute kidney injury, GFR glomerular filtration rate, UTP urinary protein excretion, sAlb serum albumin, Hb hemoglobin, ALT alanine aminotransferase, AST aspartate aminotransferase, Ca calcium, P phosphorus, K potassium, HCO₃⁻ bicarbonate, hsCRP high-sensitivity C-reactive protein, uKIM-1 urinary kidney injury molecule-1, FeNa fractional excretion of sodium, RFI renal failure index

111 of the 184 patients were in the stable renal function group, and 73 patients were in the renal function deterioration group. Of the 98 patients with renal AKI, 49 were in the stable renal function group, and 49 were in the renal function deterioration group (Fig. 1).

Of the 184 patients with AKI, the ages ranged from 18 to 99 years, and the median age was 53.00 (31.00, 64.75) years. The male/female ratio was 1.75:1, and the mean follow-up duration was 12.2 ± 1.06 months. The basic serum creatinine (sCr), basic eGFR and basic 24-h total urine protein levels were 1.12 (0.87, 2.40) mg/dl, 66.68 (28.10, 94.18) ml/min/1.73 m² and 3.78 (1.47, 9.08) g, respectively. The baseline creatinine was considered the lowest value within 3 months prior to diagnosis of AKI.

There were 71 patients with previous chronic renal disease (CKD). CKD is defined according to Kidney Disease Improving Global Outcomes (KDIGO) Clinical

Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease [12]. The uKIM-1 level at the time of AKI occurrence was 2.37 (1.10, 6.22) ng/mg, and the peak level of creatinine was 2.43 (1.41, 3.74) mg/dl. There were 123 patients in AKI stage I, 26 patients in stage II and 35 patients in stage III. Patients with renal AKI accounted for 53.26 %. The clinical etiology of AKI included insufficient renal blood perfusion or ischemia (22 %) (insufficient volume, gastrointestinal loss, cardiac failure, or renal vascular factors), nephrotoxicity (20 %) (nephrotoxic agents and contrast medium injury, etc.), infection factor (23 %) (sepsis, severe pneumonia and any kind of infection that caused renal injury), aggravation or activation of glomerular disease (19 %), and obstruction (11 %). The proportion of patients with renal function progression was 39.67 % at the one-year follow up (Table 1).




Fig. 2 Western blot analysis of urinary kidney injury molecule-1 (*uKIM-1*) with and without established acute kidney injury (AKI). All patients with established AKI had easily detectable *uKIM-1*. The *uKIM-1* levels in urine from patients who were clinically diagnosed with renal AKI were higher than in patients with transient AKI: **P* < 0.05, ***P* < 0.001. CKD chronic kidney disease




Fig. 3 Spearman correlation analyses. **a** The urinary kidney injury molecule-1 (*uKIM-1*) content was positively correlated with fractional excretion of sodium (*FeNa*). **b**. The *uKIM-1* content was positively correlated with the renal failure index (*RFI*). **c**. The *uKIM-1* content was positively correlated with the times of creatinine elevation

uKIM-1 detection by western blot

Western blot analysis was performed on urine specimens from six patients: two patients were clinically diagnosed with renal AKI, two patients were clinically diagnosed with transient AKI, one was a patient with CKD, and one patient was used as a normal control. uKIM-1 was undetectable in healthy control urine, and a low level was observed in the urine of the patient with CKD. In sharp contrast, all patients with established AKI had easily detectable levels of uKIM-1, and higher levels were observed in urine from patients who were clinically diagnosed with renal AKI (Fig. 2).

Correlation analysis

Spearman correlation analysis indicated that uKIM-1 positively correlated with the fractional excretion of sodium (FeNa), renal failure index (RFI) and creatinine elevation ($r = 0.887, 0.887$ and 0.438 , respectively, $P = 0.000$) (Fig. 3).

Identification of transient AKI and renal AKI on the basis of uKIM-1 levels


The patients were classified into transient AKI (86 patients) and renal AKI groups (98 patients) on the basis of renal function recovery during short-term follow up (≤ 48 h). Comparisons between groups demonstrated that the prognosis of the renal AKI group was significantly inferior to the transient AKI group. Of the 86 patients with transient AKI, 44 presented with a FeNa ≥ 1 %, and 48 presented with an RFI ≥ 1 %. Comparisons between groups indicated that the uKIM-1 level of the renal AKI group was significantly higher than that of the transient AKI group (Table 2, Fig. 4).

ROC curve analysis revealed that the area under the curve (ROC-AUC) was 0.691 ($P = 0.000$) for the diagnosis of renal AKI on the basis of uKIM-1. The sensitivity was 66.3 % when the cutoff point of uKIM-1 level was 2.14 ng/mg, and the specificity was 64.7 % (Fig. 5).

Table 2 Comparison between the transient AKI group and the renal AKI group

	Transient AKI (N = 86)	Renal AKI (N = 98)	P
uKIM-1 (ng/mg)	1.52 (0.57, 4.29)	3.24 (1.56, 8.53)	0.000
FeNa ≥ 1 % (n (%))	44 (51.16 %)	82 (83.67 %)	0.000
RFI ≥ 1 % (n (%))	48 (55.81 %)	88 (89.80 %)	0.000
Progression of renal failure (n (%))	24 (27.91 %)	49 (50.00 %)	0.000

AKI acute kidney injury, uKIM-1 urinary kidney injury molecule-1, FeNa fractional excretion of sodium, RFI renal failure index



Analysis of long-term prognosis predictions on the basis of uKIM-1 levels

Analysis of long-term prognosis for patients with renal AKI


Of the 98 patients with renal AKI at the regular one-year follow up, 49 were in the stable renal function group, and 49 were in the renal function deterioration group. There was no difference by sex in the composition of the groups. However, patients in the renal function deterioration group were older than those in the renal function stable group, and their basic renal function was inferior, with a high peak value of creatinine after AKI. More patients in the renal function deterioration group presented with FeNa ≥ 1 % and RFI ≥ 1 %, and their uKIM-1 levels were significantly higher than the stable renal function group (Table 3).

Gradual Cox regression analysis indicated that patients with renal AKI had higher uKIM-1 levels with poorer long-term renal prognosis. The risk of renal function deterioration following AKI increased by 6.4 % for each 1 ng/mg increase in uKIM-1. The prognosis of patients with renal AKI who presented with FeNa ≥ 1 % was inferior to that of patients with FeNa < 1 % (Table 4).

The ROC-AUC for the prediction of renal function deterioration in patients with renal AKI when the uKIM-1 level was 0.680. When the cutoff for uKIM-1 was 2.46 ng/mg, the sensitivity was 78.6 %, and the specificity 57.9 % (Fig. 6). The K-M curve indicated that uKIM-1 > 2.46 ng/mg positively correlated with poor long-term renal prognosis in patients with renal AKI ($P = 0.000$) (Fig. 7).

Analysis of long-term prognosis for patients with AKI

Of the 184 patients with AKI after the regular one-year follow up, 111 patients were in the stable renal function



	ROC-AUC (CI 95%)	P	Cut-off (Sensitivity, Specificity)
uKIM-1 (ng/mg)	0.691(0.606, 0.776)	0.000	2.14(68.3%, 64.7%)

Fig. 5 Receiver operating characteristic area under the curve (ROC-AUC) of renal acute kidney injury according to urinary kidney injury molecule-1 (uKIM-1) level

group, and 73 patients were in the renal function deterioration group. There was no difference by sex in the composition of the groups. However, patients in the renal function deterioration group were older than patients in the stable renal function group, and their basic renal function was inferior, with a high peak value of creatinine following AKI. More patients in the renal function deterioration group presented with FeNa $\geq 1\%$ and

RFI $\geq 1\%$, and the uKIM-1 level was significantly higher than that of the stable renal function group (Table 5).

Gradual Cox regression analysis indicated that older patients had lower basic eGFR, higher uKIM-1, and poorer long-term renal prognosis. The risk of renal function deterioration after AKI increased by 3.3% for each one-year increase in age. The risk of renal function deterioration after AKI increased by 2.4% for each

Table 3 Comparison between the renal function deterioration group and the stable renal function group after one-year follow up in patients with renal acute kidney injury

Characteristics	Stable renal function (n = 49)	Renal function deterioration (n = 49)	P
Age, years	53.00 (32.75, 65.00)	62.00 (45.00, 72.00)	0.039
Male sex, (n (%))	30 (61.22 %)	31 (63.27 %)	1.000
Baseline serum creatinine (mg/dl)	1.12 (0.87, 1.88)	2.23 (1.11, 3.13)	0.006
Baseline estimated GFR (ml/min/1.73 m ²)	74.00 (39.31, 92.33)	30.52 (17.01, 53.93)	0.001
Baseline 24 hUTP (g/24 h)	6.12 (2.13, 9.34)	5.32 (1.58, 9.48)	0.563
Peak serum creatinine (mg/dl)	2.20 (1.49, 3.63)	3.43 (2.44, 4.51)	0.002
uKIM-1 (ng/mg)	2.05 (1.17, 6.33)	5.15 (2.48, 11.06)	0.006
FeNa $\geq 1\%$ (n (%))	26 (53.06 %)	44 (89.80 %)	0.000
RFI $\geq 1\%$ (n (%))	32 (65.31 %)	47 (95.92 %)	0.000

Conversion factor for serum creatinine in mg/dL to mmol/L, $\times 88.4$. GFR glomerular filtration rate, UTP urinary protein excretion, uKIM-1 urinary kidney injury molecule-1, FeNa fractional excretion of sodium, RFI renal failure index

Table 4 Cox regression shows the independent risk factors for renal function progression in patients with renal acute kidney injury

Characteristics	Univariate analysis		Multivariate analysis	
	Relative risk	P	Relative risk	P
Age, years	1.025 (1.006, 1.044)	0.009		
Male sex				
Baseline estimated GFR (ml/min/1.73 m ²)	0.974 (0.959, 0.990)	0.001		
Peak serum creatinine (mg/dl)	1.002 (1.000, 1.003)	0.009		
uKIM-1 (ng/mg)	1.064 (1.036, 1.093)	0.000	1.064 (1.024, 1.106)	0.001
FeNa ≥1 %	4.510 (1.588, 12.806)	0.005	9.538 (1.264, 72.006)	0.029
RFI ≥1 %	5.486 (1.311, 22.945)	0.020		

GFR glomerular filtration rate, uKIM-1 urinary kidney injury molecule-1, FeNa fractional excretion of sodium, RFI renal failure index

decrease of 1 ml/min/1.73 m² of basic eGFR. The risk of renal function deterioration after AKI increased by 1.8 % for each 1 ng/mg increase in uKIM-1 (Table 6).

The ROC-AUC values for the prediction of renal function deterioration with age, uKIM-1 level and basic eGFR level were 0.687, 0.703 and 0.833, respectively. When the age cutoff point was 59.5 years, the sensitivity was 54.1 %, and the specificity 78.4 %. When the cutoff point of the uKIM-1 level was 2.37 ng/mg, the sensitivity was 78.4 %, and the specificity 60.8 %. When the cutoff point of the eGFR level was 60.35 ml/min/1.73, the sensitivity and specificity were 71.2 % and 76.3 %, respectively (Fig. 8).

The K-M curve revealed that uKIM-1 > 2.37 ng/mg positively correlated with poor long-term renal prognosis (P = 0.000) (Fig. 9).

Discussion

The incidence rate of AKI is high, and is showing a trend of annual increase. AKI is common in hospitalized patients, especially critical patients; critical patients with AKI have high mortality rates. Recent epidemiological data have indicated that even mild and reversible AKI leads to persistent injuries of renal tissues, and severe AKI results in an irreversible decrease in renal function, which increases the risk of death. Several observational




Fig. 6 Receiver operating characteristic area under the curve (ROC-AUC) of renal function progression in patients with renal acute kidney injury




Fig. 7 Urinary kidney injury molecule-1 (*uKIM-1*) level and kidney prognosis in patients with renal acute kidney injury patients. *uKIM-1* > 2.46 ng/mg was positively related to poor prognosis. *Cum* cumulative

studies have demonstrated that acute renal injuries are significantly correlated with the subsequent development of chronic renal disease [13]. For example, many observational studies have demonstrated that some renal function is often recovered in a large proportion of patients with acute renal injury and patients without previous renal disease, but symptoms in these patients subsequently develop end-stage chronic renal disease. However, the long-term prognosis of AKI is not clear, and markers of early AKI prognosis are lacking.

This study followed 184 patients with AKI of different etiological types, and found that nearly 40 % of patients presented with deterioration in renal function after one year. On further analysis of these patients with AKI, 86 patients had recovered renal function within short-term follow up (within 48 h) and 98 patients did not recover renal function: 50 % of patients who did not recover

renal function within 48 h had renal function deterioration within one year. Previous studies [14, 15] have also demonstrated that AKI results in CKD and affects the course of CKD. AKI is generally reversible when serum creatinine concentrations recover, but there may be sub-clinical injury of the kidney and other organs, resulting in CKD and ESRD.

Methods that indicate the prognosis of AKI during early stages are lacking. Basic studies [16, 17] have demonstrated that renal ischemia reperfusion injury alters the permeability of endothelial cells, decreases blood capillaries around the tubules, and creates an oxygen deficiency around the tubules and in the tissue space, which eventually results in fibrosis and gradually changes the kidney structure. Therefore, these patients develop CKD more easily. KIM-1 is an outstanding marker of renal injury [18], and KIM-1 is increased in

Table 5 Comparison between the renal function deterioration group and the stable renal function group after one-year follow up in patients with acute kidney injury

Characteristics	Stable renal function (n = 111)	Renal function deterioration (n = 73)	P
Age, years	42.00 (29.00, 59.00)	59.00 (45.00, 71.00)	0.000
Male sex	73 (65.77 %)	44 (60.27 %)	0.531
Baseline serum creatinine (mg/dl)	0.96 (0.76, 1.32)	2.17 (0.99, 3.22)	0.000
Baseline estimated GFR (ml/min/1.73 m ²)	84.39 (50.57, 111.86)	31.21 (17.09, 61.04)	0.000
Baseline 24 hUTP (g/24 h)	3.38 (1.44, 8.83)	2.23 (1.48, 9.06)	0.802
Peak serum creatinine (mg/dl)	1.92 (1.27, 3.04)	3.43 (2.31, 4.63)	0.000
uKIM-1 (ng/mg)	1.57 (0.70, 3.89)	4.41 (1.69, 8.72)	0.000
FeNa ≥1 % (n (%))	61 (54.95 %)	65 (89.04 %)	0.000
RFI ≥1 % (n (%))	71 (63.96 %)	65 (89.04 %)	0.000

GFR glomerular filtration rate, UTP Urinary protein excretion, uKIM-1 urinary kidney injury molecule-1, FeNa fractional excretion of sodium, RFI renal failure index


Table 6 Cox regression shows the independent risk factors for renal function progression in patients with acute kidney injury

Characteristics	Univariate analysis		Multivariate analysis	
	Relative risk	P	Relative risk	P
Age, years	1.033 (1.018, 1.047)	0.000	1.032 (1.008, 1.057)	0.009
Male sex				
Baseline estimated GFR (ml/min/1.73 m ²)	0.976 (0.965, 0.987)	0.000	0.974 (0.962, 0.986)	0.000
Peak serum creatinine (mg/dl)	1.002 (1.001, 1.003)	0.001		
uKIM-1 (ng/mg)	1.018 (1.008, 1.029)	0.000	1.018 (1.004, 1.031)	0.009
FeNa ≥1 %	3.314 (1.622, 6.768)	0.001		
RFI ≥1 %	2.670 (1.199, 5.948)	0.016		

GFR glomerular filtration rate, uKIM-1 urinary kidney injury molecule-1, FeNa fractional excretion of sodium, RFI renal failure index

prerenal AKI. KIM-1 increases significantly in renal AKI [19]. The fractional excretion of FeNa and the RFI are often used to define renal AKI, but there are certain limitations [20]. This study demonstrated that uKIM-1 was significantly increased in patients with renal AKI. The ROC-AUC indicated that high uKIM-1 was valuable in the diagnosis of renal AKI. Thus, high uKIM-1 indicates a high possibility of severe renal injury.

In previous studies of obstructive nephropathy [21, 22], uKIM-1 in patients with deterioration of renal function were significantly higher than in patients with stable renal function among patients with obstructive nephropathy who developed AKI. After one year, uKIM-1 in the patients with deterioration in renal function was significantly higher than that patients with stable renal function in 90 patients with obstructive nephropathy, regardless of






Fig. 9 Urinary kidney injury molecule-1 (*uKIM-1*) and kidney prognosis in patients with acute kidney injury. *uKIM-1* > 2.37 ng/mg was positively related with poor prognosis. *Cum* cumulative

their AKI status, which indicates that *uKIM-1* has a predictive value in the long-term prognosis of patients with obstructive nephropathy. A large clinical study [23] performed renal puncture biopsy in patients with renal disease of different etiological types and demonstrated that *KIM-1* is secreted in proximal renal tubular epithelial cells; further, the tissue expression of *KIM-1* is associated with fibrosis and inflammation. *uKIM-1* reflects *KIM-1* levels in tissues, which is related to renal tubulointerstitial inflammation and renal function. This relationship indicates that *KIM-1* is not only a biological marker of acute renal proximal tubular injury but also a marker of tubulointerstitial chronic inflammation and fibrosis [24].

This study demonstrated that *uKIM-1* levels in the renal function deterioration group were significantly higher than those in the stable renal function group in patients with renal AKI after a regular one-year follow up. The risk of renal function deterioration following AKI increased by 6.4 % for each 1 ng/mg increase in *uKIM-1*. Analysis of the ROC curve indicates that the *uKIM-1* level better predicted the long-term prognosis of patients with renal AKI. We further analyzed the 184 included patients with AKI, and the results indicated that *uKIM-1* in the renal function deterioration group was significantly higher than that in the stable renal function group. Age, basic eGFR, and *uKIM-1* were risk factors for poor renal prognosis. The K-M curve demonstrated that *uKIM-1* > 2.37 ng/mg positively correlated with poor long-term renal prognosis. Our study indicates that *uKIM-1* better predicts the long-term prognosis of patients with AKI.

This was a single-center study with a small sample size; changes in renal function were followed up for one year, but no further follow up was performed to identify changes in marker levels. Therefore, a larger, multi-center study is required to verify the results of this study, and follow up must be performed to detect changes in marker levels during the progression of renal diseases, to further prove the value of *uKIM-1* for the monitoring of renal prognosis.

Conclusions

The prognosis of patients with AKI is poor, and there is a risk of renal function progression. High *uKIM-1* indicates a high possibility of severe renal injury. *uKIM-1* accurately predicted the renal prognosis of patients with AKI, and they may be used as an early screening indicator of poor renal prognosis. The results of this study suggest novel treatment strategies and may help clinical physicians to engage in early interventions to slow the progression of renal deterioration after AKI.

Acknowledgements

The study was sponsored by the Hong Kong, Macao and Taiwan Science & Technology Cooperation Program of China (2014DFT30090) and the National Natural Science Foundation of China (81373865, 81370794, 81573748 and 81570604), and by grants (14140903200) from the Science and Technology Commission of Shanghai Municipality, China. The study was also sponsored by the Program of Shanghai Academic Research Leader (16XD1401900). Program ZHYY-ZXYJHZX-1-02 from the Shanghai Health Bureau was also included in the funding report.

Funding

The authors received no specific funding for this work.

Availability of data and materials

All relevant data are within the paper and its supporting information files. All data are fully available without restriction.

Authors' contributions

YX performed the experiments, analyzed the data and drafted the manuscript. QW performed the experiments and helped to draft the manuscript. CW helped to perform the experiments. CQ helped to analyze the data. ZN conceived and designed the experiments and contributed reagents, materials and analysis tools. SM conceived and designed the experiments, revised the manuscript and contributed reagents, materials and analysis tools. All authors read and approved the final manuscript.

Competing interests

The authors declare they have no competing interests.

Consent for publication

All authors read and approved the final manuscript.

Ethics approval and consent to participate

The Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University approved the study, and all participants provided written informed consent.

Received: 25 April 2016 Accepted: 15 August 2016

Published online: 10 September 2016

References

- Kidney Disease Improving Global Outcomes AKI Guideline Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl.* 2012;2:1–138.
- Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? *Kidney Int.* 2015;87:46–61.
- Md Ralib A, Mat Nor MB. Acute kidney injury in a Malaysian intensive care unit: Assessment of incidence, risk factors, and outcome. *J Crit Care.* 2015;30:636–42.
- Canaud G, Bonventre JV. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. *Nephrol Dial Transplant.* 2015;30:575–83.
- Berger K, Moeller MJ. Mechanisms of epithelial repair and regeneration after acute kidney injury. *Semin Nephrol.* 2014;34:394–403.
- Leung KC, Tonelli M, James MT. Chronic kidney disease following acute kidney injury-risk and outcomes. *Nat Rev Nephrol.* 2013;9:77–85.
- Sawhney S, Mitchell M, Marks A, et al. Long-term prognosis after acute kidney injury(AKI): what is the role of baseline kidney function and recovery? A systematic review. *BMJ Open.* 2015;5:e006497.
- Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. *J Am Soc Nephrol.* 2011;22:810–20.
- Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem.* 2007;53:766–72.
- Doi K, Katagiri D, Negishi K, et al. Mild elevation of urinary biomarkers in prerenal acute kidney injury. *Kidney Int.* 2012;82:1114–20.
- Macedo E, Bouchard J, Soroko SH, et al. Fluid accumulation, recognition and staging of acute kidney injury in critically ill patients. *Crit Care.* 2010;14:R82.
- The Kidney Disease: Improving Global Outcomes (KDIGO) organization. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl.* 2013;3:1–150.
- Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med.* 2014;371:58–66.
- Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. *Kidney Int.* 2012;82:516–24.
- Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. *Kidney Int.* 2012;81:442–8.
- Basile DP. The endothelial cell in ischemic acute kidney injury: implications for acute and chronic renal function. *Kidney Int.* 2007;72:151–6.
- Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. *J Am Soc Nephrol.* 2003;14:1549–58.
- Coca SG, Yalavarthy R, Concato J, et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. *Kidney Int.* 2008;73:1008–16.
- Nejat M, Pickering JW, Devarajan P, et al. Some biomarkers of acute kidney injury are increased in pre-renal acute injury. *Kidney Int.* 2012;81:1254–62.
- Perazella MA, Coca SG, Hall IE, et al. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. *Clin J Am Soc Nephrol.* 2011;5:402–8.
- Xue W, Xie Y, Mou S, et al. Diagnostic performance of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidney injury in an obstructive nephropathy patient. *Nephrology.* 2014;19:186–94.
- Xie Y, Xue W, Mou S, et al. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes. *PLoS One.* 2014;9:e112865.
- van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. *J Pathol.* 2007;212:209–17.
- Alge JL, Arthur JM. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. *Clin J Am Soc Nephrol.* 2015;10:147–55.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

